Ser714
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.3
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser714  -  EXO1 (human)

Site Information
CNIKLLDsQSDQTSK   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 482301
Associated spectra:  1 CST

In vivo Characterization
Methods used to characterize site in vivo:
immunoprecipitation ( 6 ) , mass spectrometry ( 2 , 3 , 4 , 5 , 6 , 7 , 8 ) , mutation of modification site ( 6 ) , phospho-antibody ( 1 , 6 ) , western blotting ( 1 , 6 )
Disease tissue studied:
HER2 positive breast cancer ( 2 ) , luminal A breast cancer ( 2 ) , luminal B breast cancer ( 2 ) , breast cancer, triple negative ( 2 )
Relevant cell line - cell type - tissue:

Upstream Regulation
Treatments:
camptothecin ( 1 ) , hydroxyurea ( 6 ) , ionizing_radiation ( 6 ) , MG132 ( 6 ) , VE822 ( 1 )

Downstream Regulation
Effects of modification on EXO1:
protein degradation ( 6 )

References 

1

Tomimatsu N, et al. (2017) DNA-damage-induced degradation of EXO1 exonuclease limits DNA end resection to ensure accurate DNA repair. J Biol Chem 292, 10779-10790
28515316   Curated Info

2

Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62
27251275   Curated Info

3

Sharma K, et al. (2014) Ultradeep human phosphoproteome reveals a distinct regulatory nature of Tyr and Ser/Thr-based signaling. Cell Rep 8, 1583-94
25159151   Curated Info

4

Zhou J (2011) CST Curation Set: 11707; Year: 2011; Biosample/Treatment: cell line, HeLa/UV; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]Q Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) ATM/ATR Substrate (S*/T*QG) (P-S/T2-100) Rabbit mAb Cat#: 6966, PTMScan(R) Phospho-ATM/ATR Substrate Motif (S*/T*QG) Immunoaffinity Beads Cat#: 6969
Curated Info

5

Zhou J (2011) CST Curation Set: 11708; Year: 2011; Biosample/Treatment: cell line, HeLa/UV; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]Q Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) ATM/ATR Substrate (S*/T*QG) (P-S/T2-100) Rabbit mAb Cat#: 6966, PTMScan(R) Phospho-ATM/ATR Substrate Motif (S*/T*QG) Immunoaffinity Beads Cat#: 6969
Curated Info

6

El-Shemerly M, et al. (2008) ATR-dependent pathways control hEXO1 stability in response to stalled forks. Nucleic Acids Res 36, 511-9
18048416   Curated Info

7

Matsuoka S, et al. (2007) ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage. Science 316, 1160-6
17525332   Curated Info

8

Possemato A (2007) CST Curation Set: 2795; Year: 2007; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]Q
Curated Info